Axonics Debt to Equity Ratio 2017-2024 | AXNX
Current and historical debt to equity ratio values for Axonics (AXNX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Axonics debt/equity for the three months ending September 30, 2024 was 0.00.
| Axonics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.11B | $0.66B | 0.17 |
| 2024-06-30 | $0.10B | $0.64B | 0.16 |
| 2024-03-31 | $0.09B | $0.63B | 0.14 |
| 2023-12-31 | $0.08B | $0.64B | 0.13 |
| 2023-09-30 | $0.05B | $0.61B | 0.08 |
| 2023-06-30 | $0.05B | $0.60B | 0.08 |
| 2023-03-31 | $0.09B | $0.58B | 0.15 |
| 2022-12-31 | $0.09B | $0.57B | 0.16 |
| 2022-09-30 | $0.08B | $0.55B | 0.15 |
| 2022-06-30 | $0.08B | $0.44B | 0.17 |
| 2022-03-31 | $0.06B | $0.46B | 0.13 |
| 2021-12-31 | $0.07B | $0.48B | 0.14 |
| 2021-09-30 | $0.07B | $0.49B | 0.15 |
| 2021-06-30 | $0.06B | $0.50B | 0.12 |
| 2021-03-31 | $0.12B | $0.33B | 0.35 |
| 2020-12-31 | $0.06B | $0.29B | 0.19 |
| 2020-09-30 | $0.05B | $0.29B | 0.18 |
| 2020-06-30 | $0.05B | $0.30B | 0.17 |
| 2020-03-31 | $0.05B | $0.17B | 0.26 |
| 2019-12-31 | $0.04B | $0.18B | 0.20 |
| 2019-09-30 | $0.03B | $0.09B | 0.37 |
| 2019-06-30 | $0.03B | $0.11B | 0.28 |
| 2019-03-31 | $0.03B | $0.13B | 0.21 |
| 2018-12-31 | $0.03B | $0.14B | 0.20 |
| 2018-09-30 | $0.02B | $0.02B | 0.74 |
| 2018-06-30 | $0.00B | $0.00B | 0.00 |
| 2018-03-31 | $0.00B | $0.00B | 0.00 |
| 2017-12-31 | $0.00B | 0.00 | |
| 2017-09-30 | $0.00B | $0.00B | 0.00 |
| 2016-12-31 | $0.00B | $0.01B | 0.20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $3.603B | $0.366B |
| Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction and disrupting the SNM market. Axonics Modulation Technologies Inc. is based in Irvine, CA. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $10.500B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $5.733B | 148.28 |
| Inspire Medical Systems (INSP) | United States | $5.716B | 178.27 |
| IRhythm Technologies (IRTC) | United States | $2.729B | 0.00 |
| Privia Health (PRVA) | United States | $2.710B | 225.80 |
| Enovis (ENOV) | United States | $2.621B | 17.77 |
| Omnicell (OMCL) | United States | $2.264B | 74.08 |
| Azenta (AZTA) | United States | $2.250B | 112.17 |
| 10x Genomics (TXG) | United States | $1.898B | 0.00 |
| Schrodinger (SDGR) | United States | $1.620B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.617B | 0.00 |
| Phreesia (PHR) | United States | $1.235B | 0.00 |
| Standard BioTools (LAB) | United States | $0.763B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.586B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.571B | 0.00 |
| Talkspace (TALK) | United States | $0.569B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.528B | 91.40 |
| Health Catalyst (HCAT) | United States | $0.495B | 0.00 |
| Pulmonx (LUNG) | United States | $0.278B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.261B | 0.00 |
| TruBridge (TBRG) | United States | $0.234B | 67.96 |
| P3 Health Partners (PIII) | United States | $0.140B | 0.00 |
| American Well (AMWL) | United States | $0.136B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.098B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.063B | 0.00 |
| 111 (YI) | China | $0.056B | 0.00 |
| CareCloud (CCLD) | United States | $0.051B | 0.00 |
| Zepp Health (ZEPP) | China | $0.049B | 0.00 |
| Outset Medical (OM) | United States | $0.045B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.041B | 0.00 |
| Movano (MOVE) | United States | $0.028B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.017B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.007B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |